Menopur (Menotrophin)

Menotrophin contains both follicle‑stimulating hormone (FSH) and luteinising hormone (LH). After injection, the FSH component binds to receptors on granulosa cells, promoting the growth and maturation of ovarian follicles, while the LH component activates receptors on theca cells, supporting steroid hormone production and final follicle maturation, together leading to ovulation.

The dose of Menopur is individualized; a qualified prescriber determines the amount based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted‑reproduction protocol. Dosing may be adjusted during the treatment cycle according to serial ultrasound and hormone monitoring.

Menopur is intended for use before conception to facilitate ovulation; its safety in established pregnancy has not been established, and it is generally not recommended for use during pregnancy. Limited data are available for breastfeeding, and the drug is usually avoided while nursing unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the Menopur product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assistance with import documentation.

Menopur provides a combination of FSH and LH activity in a single preparation, whereas some alternatives, such as recombinant FSH products, contain only FSH and may require an additional LH source. The combined formulation can simplify dosing regimens and may be advantageous for patients with LH deficiency, but individual response and cost considerations influence the choice of therapy.

Menopur should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. It must not be frozen or shaken, and any unused portion should be discarded after the recommended in‑use period indicated by the manufacturer to maintain sterility and potency.

Menopur is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The medication is reconstituted with the appropriate diluent, drawn into a syringe, and administered according to the prescriber’s instructions, typically once daily during the ovarian stimulation phase of an assisted‑reproduction cycle.

The most serious adverse events include ovarian hyperstimulation syndrome (OHSS), which can cause rapid fluid shifts, thrombosis, and organ dysfunction, and multiple pregnancy, which carries higher obstetric risk. Prompt monitoring of estradiol levels and follicle size by ultrasound is essential to identify and mitigate these risks early.

Menopur is contraindicated in women with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent neoplasms, severe ovarian hyperstimulation syndrome, or known hypersensitivity to menotrophin or any excipients. It should also be used with caution in patients with significant renal or hepatic impairment.